학술논문
Evidence from routine clinical practice: EMPRISE provides a new perspective on CVOTs.
Document Type
Editorial
Author
Schernthaner, Guntram; Karasik, Avraham; Abraitienė, Agnė; Ametov, Alexander S.; Gaàl, Zsolt; Gumprecht, Janusz; Janež, Andrej; Kaser, Susanne; Lalić, Katarina; Mankovsky, Boris N.; Moshkovich, Evgeny; Past, Marju; Prázný, Martin; Radulian, Gabriela; Smirčić Duvnjak, Lea; Tkáč, Ivan; Trušinskis, Kārlis
Source
Subject
*TYPE 2 diabetes
*EVIDENCE
*HEART failure
*
*
Language
ISSN
1475-2840
Abstract
EMPA-REG OUTCOME is recognised by international guidelines as a landmark study that showed a significant cardioprotective benefit with empagliflozin in patients with type 2 diabetes (T2D) and cardiovascular disease. To assess the impact of empagliflozin in routine clinical practice, the ongoing EMPRISE study is collecting real-world evidence to compare effectiveness, safety and health economic outcomes between empagliflozin and DPP-4 inhibitors. A planned interim analysis of EMPRISE was recently published, confirming a substantial reduction in hospitalisation for heart failure with empagliflozin across a diverse patient population. In this commentary article, we discuss the new data in the context of current evidence and clinical guidelines, as clinicians experienced in managing cardiovascular risk in patients with T2D. We also look forward to what future insights EMPRISE may offer, as evidence is accumulated over the next years to complement the important findings of EMPA-REG OUTCOME. [ABSTRACT FROM AUTHOR]